AstraZeneca spinout Albireo Pharma is moving closer to securing regulatory approval for its treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC).
privacy policy | terms of use | contact us | advertise | pharma blogs | facebook | twitter
Copyright © 2025,